Amryt Pharma
Amryt Pharma, a biopharmaceutical company headquartered in Ireland (IE), is dedicated to developing innovative treatments for rare and complex diseases. Founded in 2015, Amryt has rapidly established itself in the industry, focusing on areas such as dermatology and metabolic disorders. The company’s flagship products, including AP101 for epidermolysis bullosa and AP103 for other dermatological conditions, are distinguished by their unique formulations and targeted delivery mechanisms. Amryt Pharma has achieved significant milestones, including successful product launches and strategic partnerships, positioning itself as a leader in the rare disease market. With a commitment to improving patient outcomes, Amryt continues to expand its global reach, making a meaningful impact in the lives of those affected by challenging health conditions.
DitchCarbon Score
How does Amryt Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Amryt Pharma's score of 60 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Amryt Pharma's reported carbon emissions
In 2023, Amryt Pharma reported total carbon emissions of approximately 949,619,000 kg CO2e, with emissions distributed across various scopes: 29,906,000 kg CO2e from Scope 1, 591,000 kg CO2e from Scope 2, and the majority, 949,619,000 kg CO2e, from Scope 3. This reflects a slight increase in Scope 1 emissions compared to 2022, where Scope 1 emissions were 29,715,000 kg CO2e, and Scope 3 emissions were 897,564,000 kg CO2e. In 2021, the company reported total emissions of 368,480,000 kg CO2e, with Scope 1 emissions at 27,507,000 kg CO2e, Scope 2 at 1,771,000 kg CO2e, and Scope 3 at 815,059,000 kg CO2e. This indicates a significant reliance on Scope 3 emissions, which typically encompass indirect emissions from the supply chain and product use. Despite the detailed emissions reporting, Amryt Pharma has not disclosed specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of documented reduction strategies suggests a need for further commitment to climate action within the pharmaceutical industry context.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 27,507,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 1,771,000 | 000,000 | 000,000 |
| Scope 3 | 815,059,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Amryt Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
